Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.49 |
| ▸ | EDNRA | P25101 | 6/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.39 |
| ▸ | BCL2 | P10415 | 4/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698539 | 0.87 | PTGES (0.41) | PTGESKMT2AALDH1A1TP53POLB | |
| SCHEMBL4697691 | 0.85 | PTGES (0.48) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4698138 | 0.83 | PTGES (0.44) | PTGES | |
| SCHEMBL4702217 | 0.83 | PTGES (0.43) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL4923569 | 0.83 | PPARG (0.47) | PTGES | |
| SCHEMBL4914621 | 0.83 | PPARG (0.47) | PTGES | |
| SCHEMBL3578280 | 0.82 | PTGES (0.53) | PTGESEDNRARXRARXRBMCL1 | |
| SCHEMBL3574863 | 0.81 | PTGES (0.52) | PTGESACACBACACAMCL1BCL2 | |
| SCHEMBL4923088 | 0.81 | EDNRA (0.52) | EDNRAEDNRB | |
| SCHEMBL4699431 | 0.81 | PTGES (0.58) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1778633-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005123674-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | PTGES 4/4885EDNRA 71/4885ACACB 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.